Summary: In a translational study combining diabetic mice and postmenopausal women with osteoporosis, rhPTH(1-34) improved lumbar spine bone mineral density and reactivated bone turnover more than alendronate, which underperformed in the low-turnover setting of type 2 diabetes.
PICO Summary
| Element | Detail |
|---|---|
| Population | Postmenopausal women with osteoporosis, with and without type 2 diabetes, plus a streptozotocin-diabetic C57BL/6 mouse model. |
| Intervention | rhPTH(1-34) (teriparatide) over one year (clinical arm). |
| Comparison | Alendronate (clinical and animal arms); saline in animals. |
| Outcome | rhPTH(1-34) improved lumbar spine BMD and raised P1NP, CTX, and osteocalcin in diabetic osteoporosis. Alendronate produced smaller BMD gains, particularly with coexisting diabetes, and did not reverse low turnover. No notable adverse effects over one year. |
rhPTH(1-34) vs alendronate in diabetic bone disease
RCT · postmenopausal osteoporosis + T2DM · 1 year
In postmenopausal women with diabetic osteoporosis, the anabolic agent rhPTH(1-34) improved lumbar spine BMD and restored bone turnover more than alendronate, whose effect was blunted in the low-turnover diabetic setting.
Expert Commentary
Diabetic bone disease is a trap I see clinicians fall into, because BMD looks reassuring while fracture risk quietly climbs on a substrate of low turnover and poor bone quality. That biology is exactly why this study’s logic appeals to me: if remodelling is already sluggish, suppressing it further with a bisphosphonate is mechanistically the wrong move, whereas an anabolic agent that reawakens formation makes sense, and the data here fit that story cleanly. My verdict is favourable on direction and consistent with the broader teriparatide literature, including VERO. But I am careful about the leap from this dataset to practice. It blends mouse and human work, the clinical arm is small and only a year long, and every endpoint is a surrogate, BMD and turnover markers, not the fractures I actually want to prevent. Can I use this with my patients? Yes, in a way that simply reinforces existing practice: for a postmenopausal woman with diabetes at high fracture risk, especially with suspected low turnover, I would lean toward anabolic-first therapy, anchored to fracture risk rather than BMD alone. I would want diabetes-specific fracture-outcome data before claiming true superiority.
References
Li H, Yuan L, Liu P, et al. Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease. Front Endocrinol (Lausanne). 2025;16:1657481. doi:10.3389/fendo.2025.1657481